Bayer | Ophthalmology

We're excited to be attending the 16th Annual Congress on Controversies in Ophthalmology (COPHy Congress) in Seville, Spain April 4-5!   Join us and leading global experts as we dive into the latest debates and challenges in ophthalmology. We can't wait to engage in thought-provoking discussions and share insights that drive the future of eye care. Will we see you there?   #Ophthalmology #COPHy202

Extended durability in treatment is about more than convenience—it’s about creating meaningful impact.   At Bayer, as Professor Paolo Lanzetta highlights, extended durability means reducing the burden on patients and healthcare systems, while freeing up time and resources to reach even more individuals in need. Watch to learn more.   #InnovationInOphthalmology

Are you joining us at Angiogenesis 2025? We are proud to participate in the 22nd annual Angiogenesis, Exudation, and Degeneration symposium, hosted by the Bascom Palmer Eye Institute on February 8, 2025.   This highly anticipated virtual event will bring together world-leading scientists, clinicians, and researchers to explore groundbreaking therapies and advancements for retinal diseases. Find out more and register ⬇️ https://lnkd.in/ewDWCYj8   #Angiogenesis2025 #Ophthalmology #RetinalCare #Innovation

At Bayer Ophthalmology, we’re committed to addressing unmet needs in patient care by fostering collaboration, innovation, and knowledge sharing. Together with our partners, we aim to break boundaries and deliver meaningful solutions for those living with retinal diseases.   Only through partnership can we turn today’s challenges into tomorrow’s breakthroughs 🌟   #UnmetNeeds #Ophthalmology #Innovation

This year, we're excited to be exploring new horizons, sharing breakthroughs in ophthalmology and collaborating with some of the most impressive experts in the industry, so we can continue supporting the community who inspire us every day. Stay tuned for updates, and let’s make 2025 a year of impact together. #Ophthalmology

As we step into 2025, Anna Braeken, Vice President, Global Ophthalmology Lead at Bayer HealthCare Pharmaceuticals, shares her reflections on the year ahead ⬇️   Here’s to a year of innovation, collaboration, and meaningful progress.   #Ophthalmology

How do you see AI transforming patient care and optimizing clinic operations? Comment below your thoughts on how AI can shape the future of eye health. To give insights on this topic, Professor Anat Loewenstein is joined by Dr. John Kitchens, Vitreoretinal Surgeon with Retina Associates of Kentucky, USA in this new episode of “A Chat with Anat”. Listen on Spotify (https://lnkd.in/e9YHWzux) or Apple (https://lnkd.in/e9gkq_8G) to hear them discuss the importance of holistic patient care, and the latest advances in home monitoring technologies in retinal disease.   Explore more episodes of “A Chat with Anat” on Spotify (https://lnkd.in/e_k4fqpM) or Apple (https://lnkd.in/e6svNuaQ), to hear Anat discuss other key topics with internationally renowned experts on how to enhance care and optimize treatment for patients with retinal disease. #Education #OptimiseCare

How do you tailor treatment for your patients with nAMD according to their macular neovascularization (MNV) subtypes? Let us know in the comments below. To learn more, visit Spotify (https://lnkd.in/eBGhhNpa) or Apple (https://lnkd.in/e2NVCnys) to hear Professor Anat Loewenstein and Vision Academy member Professor Nicole Eter discuss how MNV is characterized and the different diagnostic tools used to classify the subtypes. Click here (https://lnkd.in/e2NVCnys) to download the Vision Academy Viewpoint discussed in this episode, and recommendations on characterizing macular neovascularization. 

As we reflect on the past year, we are deeply grateful to everyone who has been part of Bayer Ophthalmology’s journey.   Looking ahead to 2025, our commitment remains unwavering: to reduce the global impact of visual impairment and continue striving to improve care and outcomes for patients worldwide.   Thank you for following, and stay tuned for more updates, insights, and innovations in the coming year!   #Ophthalmology 

Our partnership with ESASO exemplifies innovation in ophthalmology through focusing on advancing research and optimizing clinical studies in retinal diseases.   This collaboration is a testament to the power of shared expertise and a commitment to improving outcomes for patients with retinal conditions.   #OphthalmologyInnovation #PartnershipsInResearch #FutureOfVision